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AB S T R A C T
Malignant glioma cells maintain an elevated intracellular pH (pHi) within hypoxic ischemic
tumor microenvironments through persistent activation of sodium proton transport (McLean
et al., 2000). Amiloride has been reported to selectively kill human malignant glioma cell lines
but not primary astrocytes (Hegde et al., 2004). While amiloride reduces pHi of malignant
gliomas by inhibiting isoform 1 of sodium proton exchange (NHE1), direct acidification was
shown to be cytostatic rather than cytotoxic. At cytotoxic concentrations, amiloride has
multiple drug targets including inhibition of NHE1 and sodium calcium exchange. Amiloride's
glioma cytotoxicity can be explained, at least in part, by dual inhibition of NHE1 and of Na+
dependent calcium efflux by isoform 1.1 of the sodium calcium exchanger (NCX1.1) , which
increases [Ca2+]i and initiates glioma cell demise. As a result of persistent NHE1 activity,
cytosolic free levels of sodium ([Na+]i) in U87 and C6 glioma cells are elevated 3 fold, as
compared with normal astrocytes. Basal cytosolic free calcium levels ([Ca2+]i) also are increased
5 fold. 2′, 4′ dichlorobenzamil (DCB) inhibits the sodium dependent calcium transporter
(NCX1.1) much more potently than NHE1. DCB was employed in a concentration dependent
fashion in glioma cells to selectively inhibit the forward mode of NCX1.1 at ≤1 μM, while dually
inhibiting both NHE1 and NCX1.1 at ≥20 μM. DCB (1 μM) was not cytotoxic to glioma cells, while
DCB (20 μM) further increased basal elevated levels of [Ca2+]i in glioma cells that was followed by
cell demise. Cariporide and SEA0400 are more selective inhibitors of NHE1 and NCX1.1 than
amiloride or DCB, respectively. Individually, Cariporide and SEA0400 are not cytotoxic, but in
combination induced glioma cell death. Like amiloride, the combination of Cariporide and
SEA0400 produced glioma cell death in the absence of demonstrable caspase activation.

1.

Introduction

Malignant gliomas (WHO grades 3 and 4) are the most
prevalent primary adult brain tumors with a recurrence rate
exceeding 90% within two years following conventional
therapeutic modalities (Legler et al., 1999; Brandes et al.,
1999). These rapidly proliferating and infiltrating primary
astroglial cancers outgrow their neovascularization induced
by vasogenic endothelial growth factor (VEGF) and create
hypoxic ischemic tumor domains containing necrotic glioma
cells bordered by non proliferating, pseudopallisading glioma
cells and proliferating glioma cells (Gorin et al., 2004). Glioma
necrosis remains one of the most consistent pathological
features predictive of glioma recurrence and a worsened
clinical prognosis (Brandes et al., 1999; Compostella et al.,
2007). We and others reported that glioma cells survive and
proliferate within these hypoxic ischemic tumor microenvir
onments (Gorin et al., 2004; Korkolopoulou et al., 2007). The
resultant extracellular acidosis in hypoxic ischemic tumor
microenvironments is associated with glioma cell cycle arrest.
We found that acidified glioma cells having high levels of
nuclear cyclin D1 enter cell cycle arrest at external pH (pHext) 6.0,
are capable of surviving prolonged acidosis, and resume
proliferation when the pHext of the tumor microenvironment is
normalized (Schnier et al., 2008). Not surprisingly, hypoxic
ischemic glioma cells are reported to possess increased resis
tance to radiation therapy and alkylating agents such as BCNU
and temozolomide (Barker et al., 1996; Vaupel and Mayer, 2007;
Dinca et al., 2007). Recent clinical experience treating malignant
gliomas with bevacizumab indicates that anti VEGF therapy is
cytostatic and can be followed by the recurrence of disseminated
glioma initiating cells (Chamberlain and Johnston, 2009; Lamszus
et al., 2003). Therefore, it is necessary to investigate new cytotoxic
agents targeting these glioma initiating cells. Amiloride, an FDA
approved diuretic, is cytotoxic to glioma cells in the micromolar
range and previously reported to be non toxic to primary
astrocytes (Hegde et al., 2004). In vivo, amiloride has been
identified as killing proliferating and non proliferating perine
crotic glioma cells in perinecrotic regions in an immunodeficient
murine intracerebral human U87 glioma xenograft model (Gorin,
2007).
Surprisingly, 31P NMR studies in individuals with WHO grade
3 and 4 gliomas reported normocidic or elevated pHtot within the
tumors despite their increased glycolytic fluxes (Maintz et al.,
2002). We have measured the pHi of several malignant glioma
cell lines, including human U87, U251, U118 and murine C6, and
determined that all these glioma cell lines maintain an alkalotic
pHi between 7.2 and 7.4 in a bicarbonate depleted environment
(McLean et al., 2000). Their intracellular alkalosis is a conse
quence of persistent activity of NHE1, which maintains an
elevated intracellular pH optimized for non oxidative glycolysis
in these highly metabolically active cancers (Gorin et al., 2004;
Griguer et al., 2005). Inhibiting NHE1 in human malignant
glioma cell lines in bicarbonate free media reduced their
elevated pHi to that of normal astrocytes (6.9 7.0) (McLean
et al., 2000). By contrast, astrocytes do not activate NHE1 while
maintaining pHi of 6.9 7.0 in the normal brain milieu and are not
acidified by NHE1 inhibition (McLean et al., 2000). Astrocytes and
glioma cell lines additionally express NCX1.1 and acid sensing

ion channels (ASICs) (Goldman et al., 1994; Amoroso et al., 1997;
Vila Carriles et al., 2006). ASIC1a generates constitutive inward
sodium and calcium currents in several glioma cell lines
thought to enhance proliferation and mobility, but not alter
their viability (Vila Carriles et al., 2006).
Both NHE1 and ASIC1a are blocked by amiloride, and it has
been proposed that amiloride selectively kills specific cancer
cell types by reducing their pHi and thereby inhibiting non
oxidative glycolysis (Tannock and Rotin, 1989; Reichert et al.,
2002; Wu et al., 2007). However, neither acidifying U87 or U118
glioma cell lines to pHi 6.9 by bathing them in reduced pH media
(6.8) or selectively inhibiting NHE1 with Cariporide (HOE642),
was cytotoxic (Hegde et al., 2004). Cariporide inhibits NHE1 with
an IC50 of 26 nM (Masereel et al., 2003), and in contrast to
amiloride, has not been shown to inhibit ASICs or NCX1.1. The
concentration range of amiloride (100 500 μM) capable of
selectively killing either proliferating (pHext 7.0) or non
proliferating human malignant glioma cell lines (pHext 6.0),
while remaining non toxic to normal brain cell types, indicates
that further study of its cytotoxic mechanisms of action could
lead to the development of more potent anti cancer agents.
An important physiological consequence of persistent
NHE1 activity in glioma cells would be an anticipated increase
in [Na+]i; consistent with the depolarized membrane poten
tials reported in the human U87 glioma cell line ( 48 to +
15 mV) (Ducret et al., 2003). This magnitude of depolarization
in glioma cells, as compared with normal astrocytes ( 80 mV)
(Perez Velazquez et al., 1996), is predicted to increase
intracellular calcium influx via voltage activated plasmalem
mal channels and sodium dependent calcium transport
mechanisms, as we reported in stretch injured astrocytes
(Floyd et al., 2005) and others have described in hypoxic
cardiomyocytes following reperfusion injury (Wang et al.,
2007). However, the specific cellular mechanisms underlying
the calcium loading of depolarized malignant glioma cells is
beyond the scope of this investigation which is focused upon
amiloride induced glioma demise.
In this study, we demonstrate that malignant glioma cells
maintain elevated levels of [Na+]i and [Ca2+]i in comparison to
normal astrocytes. These ionic alterations could explain the
selective killing of glioma cells by amiloride at concentrations
that inhibit Na+ dependent H+ efflux by NHE1 and Na+
dependent Ca2+ efflux (“forward mode”) by NCX1.1, further
elevating [Ca2+]i to cytotoxic levels. Selective pharmacological
inhibition of either NCX1.1 or NHE1 is not cytotoxic to glioma
cells. However, dual inhibition of NHE1 and the forward mode
of NCX1.1 further elevate [Ca2+]i and precede observed glioma
cell demise. A summary diagram of the ionic transporters,
intracellular calcium stores, and pharmacological agents
evaluated in this study is summarized in Fig. 1.

2.

Results

2.1.
Intracellular levels of cytosolic free sodium are elevated
in glioma cells
Initial basal concentrations of cytosolic free sodium [Na+]i are 3
to 3.5 fold higher in U87 and C6 glioma cells, respectively, as
compared with primary astrocytes (Fig. 2). Addition of the non
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Fig. 1 – Panel A: Basal conditions of sodium-mediated exchangers and intracellular calcium stores in glioma cells.
Panel B: {1} Inhibition of sodium-mediated proton exchange (NHE1) by Cariporide. {2} Inhibition of sodium-mediated calcium
exchange (NCX1.1) by dichlorobenzamil (1 μM DCB) or SEA0400. {1} and {2} Dual inhibition of NHE1 and NCX1.1 by either
amiloride, DCB (20 μM), Cariporide + DCB (1 μM), or Cariporide + SEA0400. {3} Release of calcium from endoplasmic reticulum by
thapsigargin (TG). {4} Release of calcium from mitochondria by carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP).
{5} Extracellular calcium entry by the ionophore, ionomycin. See text for experimental details.

fluorescent, reversible NHE1 inhibitor HOE694 to either of these
two glioma cell lines (Figs. 2A, B) reduced [Na+]i at time 0 to
concentrations comparable to that of astrocytes (~10 mM,
Fig. 2C). Replacement of buffer without HOE694 at 5 min increased
[Na+]i to their initially elevated basal levels of 32 mM ±2 within 20
60 min. These NHE1 inhibitor studies demonstrate that in a
bicarbonate free environment, elevated [Na+]i in glioma cells is
primarily a consequence of persistent NHE1 activity that is
associated with their elevated pHi (Fig. 1, panel A).

compared with time matched controls, based upon the
manual trypan blue exclusion assay to count dead cells.
Using the WST assay to measure metabolically active cells,
only 27 ± 2% of glioma cells were viable, compared with
controls. The ionomycin experiments demonstrated that
directly increasing levels of free cytosolic calcium by increas
ing calcium influx produced glioma cell demise.

2.2.
Intracellular levels of free calcium are elevated in
glioma cells

The insensitivity of elevated [Ca2+]i to NHE1 activity is not
unexpected, given the calcium buffering by intracellular stores
and calcium efflux mechanisms previously demonstrated in
glioma cells and normal astrocytes (Floyd et al., 2005; Galiano
et al., 2004). Thapsigargin (TG) inhibits calcium ATPase to
release calcium from TG sensitive stores in the endoplasmic
reticulum. Incubating U87 glioma cells and astrocytes with TG
(1 μM) caused calcium release from ER stores, reflected by an
increase in cytosolic calcium (Fig. 3C). A significant amount of
cytosolic free calcium is released by TG sensitive ER stores in
glioma cells, as compared with astrocytes. Calcium release
from ER stores was consistently observed in gliomas but not
astrocytes. However, quantification of subsequent cytosolic
free calcium concentrations, even with loading of low affinity
Fura FF, was hampered, in part by variable activation of store
operated calcium entry throughout the polyploid glioma cell
populations (Spassova et al., 2004; Kwan et al., 2008).
Importantly, [Ca2+]i released from ER stores additionally
increased the already elevated levels of cytosolic free calcium,
which returned to basal levels within 400 s (Fig. 3C).
FCCP (carbonyl cyanide p trifluoromethoxyphenyl hydra
zone) collapses the mitochondrial transmembrane potential

Basal levels of cytosolic free calcium [Ca2+]i of 400 nM and are
5 fold higher in U87 glioma cells, as compared with primary
astrocytes, in which we reported a [Ca2+]i of 80 nM (Fig. 3A)
(Floyd et al., 2005). Elevated basal levels of cytosolic free
calcium in U87 glioma cells were not altered by reduced glioma
cell pHi from 7.4 to 6.9 with acidified HEPES media of pHext 6.8
(Hegde et al., 2004), or by inhibiting NHE1 with non fluorescent
HOE694 (Fig. 3A). Therefore elevated levels of [Ca2+]i in glioma
cells, unlike [Na+]i, are not directly coupled to persistent NHE1
activity.

2.3.
Further elevation of cytosolic free calcium in glioma
cells using a calcium ionophore produces glioma cell death
Ionomycin is a bacterial ionophore that increases calcium
influx through the plasmalemma. The addition of 5 μM
ionomycin rapidly increased levels of cytosolic free calcium
released from intracellular stores by thapsigargin (TG) (Fig. 3B).
Ionomycin (5 μM) killed 54 ± 7% of U87 glioma cells at 24 h, as

2.4.

Intracellular calcium buffering and calcium efflux
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Fig. 2 – Intracellular cytosolic free sodium concentrations in
two glioma cell lines (A) C6 and (B) U87, and (C) primary rat
astrocytes treated with a reversible, non-fluorescent NHE1
inhibitor, HOE694 (100 μM), at time 0 for 5 min followed by
washout. The first data point in each graph represents basal
[Na+]i for each cell type.

(ψm) causing the release of calcium from mitochondrial stores
(Vali et al., 2000; Chalmers and Nicholls, 2003). In normal
astrocytes and other normal cell types, collapse of the trans
membrane mitochondrial potential does not demonstrably
increase [Ca2+]i (Kahlert et al., 2001). In U87 glioma cells, FCCP
caused a large increase in [Ca2+]i and a negligible [Ca2+]i increase
in normal astrocytes (Fig. 3C). Like TG, FCCP induced increase in
[Ca2+]i was transient and returned to near basal levels.

2.5.
Sodium-dependent calcium efflux by NCX1.1 is
inhibited selectively by DCB
DCB is an amiloride analog whose C2 dichloroaryl side chain
greatly enhances its inhibition of NCX1.1 ≫ NHE1, and DCB is

widely employed as an inhibitor of sodium mediated calcium
transport. Glioma cells and astrocytes express NCX1.1, there
fore it is necessary to examine the concentration dependent
inhibition of the forward and reverse modes of NCX1.1 stably
transfected into Chinese hamster ovary (CHO) cells. CHO cells
lack the ion transporters and calcium channels that partici
pate in the glutamate glutamine cycle of astroglial cell types
and which confound measurements of sodium calcium
transport in glioma cells (Ishiuchi et al., 2007; Handfield
Jones et al., 1988; Deitmer et al., 2003). Whole cell patch
electrophysiological recordings of CHO cells stably transfected
with NCX1.1 demonstrate an IC50 of 9 nM for DCB to prevent
sodium dependent calcium efflux (“forward mode”, Fig. 4A).
Furthermore, these whole patch studies demonstrate that
DCB is a much less effective inhibitor of sodium dependent
calcium influx (“reverse mode”) by NCX1.1 (IC50 22 μM, Fig. 4B).
These electrophysiological findings permitted us to employ
low concentrations of DCB (≤1 μM) to selectively block the
forward mode of NCX1.1. Compounds such as SEA0400 can be
employed to preferentially block the reverse mode of NCX1.1
with nanomolar potencies under the observed glioma condi
tions of elevated [Na+]i (Iwamoto, 2004). Higher concentrations
of DCB (≥20 μM) were employed to inhibit NHE1 (Hegde et al.,
2004), the forward mode of NCX1.1, and partially inhibit the
reverse mode of NCX1.1 (Fig. 1, panel B).

2.6.
Inhibition of the forward mode of NCX1.1 by low
concentration DCB maintains elevated Ca+i following release
from intracellular stores, but does not initiate glioma cell death
The objective of the following studies was to determine
whether the transient increase in levels of cytosolic calcium
released from intracellular stores was being moderated by the
forward mode of NCX1.1. DCB (1 μM) was added 90 100 s prior
to the addition of thapsigargin so that there was an
insufficient time for inhibition of the forward mode of
NCX1.1 to increase basal levels of cytosolic free calcium prior
to the addition of TG. DCB (1 μM) prevented the restoration of
[Ca2+]i to basal elevated levels in U87 glioma cells following
release from ER stores with TG (Fig. 3C). Significantly, DCB
(1 μM) was not cytotoxic to glioma cells nor was SEA0400
(1 μM), which preferentially blocks the reverse mode of NCX1.1
with an IC50 of 78 nM in the presence of elevated [Na+]i
(Table 1) (Lee et al., 2004). Inhibition of NCX1.1 by 1 μM DCB did
not significantly increase glioma cell death (Table 1, % trypan
blue), as compared with time matched, vehicle treated con
trols. However, low concentration DCB was observed to
possess a modest anti proliferative effect as determined by
the WST assay (% viable cells < (100 % dead cells)) (Table 1).

2.7.
Inhibition of NHE1 by Cariporide does not initiate
glioma cell death while dual inhibition of NCX1.1 and NHE1
by DCB produces caspase-independent glioma cell death
The objective of the following studies was to determine whether
dual inhibition of NHE1 and NCX1.1 contributed to amiloride's
cytotoxic effects, as measured using the trypan blue exclusion
assay. Additionally, the viabilities of treated cells, as compared
with time matched controls, were measured using the WST
tetrazolium assay to assess whether any of these agents had
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Fig. 3 – (A) Levels of cytosolic free calcium [Ca2+]i in U87 glioma cells maintained at pHext 7.4 or 6.8 in the presence or absence of the
NHE inhibitor HOE 694 (100 μM). Basal [Ca2+]i in astrocytes is between 50 and 80 nM as previously reported [26]. (B) Thapsigargin
(TG) followed by ionomycin-induced 340/380 ratio changes in U87 glioma cells loaded with Fura-2. TG initiated calcium release
from ER while the ionophore, ionomycin by increased calcium influx and produced a larger and persistent elevation in the 340/380
ratio. (C) Thapsigargin (TG) and FCCP-induced 340/380 ratio changes in primary rat astrocytes and in U87 glioma cells loaded
with Fura-2. TG or FCCP triggered calcium release in glioma cells from the ER or mitochondria, respectively, as evidenced by an
initial 2-fold increase in the 340/380 ratio in a representative study. A modest increase in the 340/380 ratios was observed in
primary astrocytes following these treatments. Upper and lower lines represent a typical experiment with U87 glioma cells or
primary astrocytes, respectively. (D) Persistent elevation of the 340/380 ratio of Fura-2 in U87 cells pretreated with DCB (1 μM) 90 s
prior to the addition of thapsigargin (10 μM). DCB (1 μM) blocked sodium-dependent calcium efflux (“forward mode”) of NCX1.1 in
U87 glioma cells to prevent moderation of elevated cytosolic calcium shown in B and C.

significant cytostatic activities independent of their cytotoxic
activities. U87 glioma cell death and total live cell numbers were
not affected by NHE1 inhibition by Cariporide (HOE642); a more
stable NHE1 inhibitor than the non fluorescent HOE694 used for
the fluorescence studies (Table 1). At higher concentrations of
DCB (20 μM) there was a marked 4 fold increase in glioma cell
death and a significant decrease in viable cells (Table 1).
Amiloride or 20 μM DCB demonstrated comparable cytotoxi
cities when tested in U87, U251 and U118 human glioma cell line
lines (Table 1). Previously, all three human cell lines had been
shown by us to maintain elevated pHi resulting from persistent
activation of NHE1 (McLean et al., 2000).

2.8.
Treatment with both SEA400 and Cariporide or DCB
and Cariporide produces caspase-independent glioma cell death
The amiloride and DCB cytotoxicity data suggested that
dual inhibition of NHE1 and the forward mode of NCX1.1

maintained elevated [Ca2+]i. Low concentration DCB (1 μM)
combined with 100 μM Cariporide killed 39 ± 4% of U87
glioma cells after 48 h when compared with time matched
controls (Table 1). A similar number of viable cells (35 ± 3%)
were detected following this treatment using the WST
live cell assay. The magnitude of glioma cell death pro
duced by 100 μM Cariporide + 1 μM DCB were not altered by
pre incubation with the pan caspase inhibitor zVAD.FMK
(34 +/ 2%).
Both amiloride and DCB reportedly inhibit ASIC2A at higher
concentrations (Page et al., 2007), so that it was useful to
employ other agents that inhibited either NHE1 (Cariporide) or
NCX1.1 (SEA0400), but did not inhibit ASIC. Neither Cariporide
nor SEA0400 individually caused glioma cell death, but in
combination they were cytotoxic to glioma cells (Table 1). The
cytotoxic effects of Cariporide + SEA0400 were not affected by
pre incubation with the pan caspase inhibitor zVAD.FMK
(Table 1).

A Inhibition of NCX 1.1 by DCB (forward mode)
Control

100 nM DCB

with Hoechst 33342. Staurosporine treatment, as a positive
control, produced the expected morphologic changes ob
served in apoptotic cells (Fig. 1S).

3.
20 pA
50 ms

1.0

IDCB/IControl

0.8
0.6

K1/2=9 nM
0.4
0.2
0.0
0

2

4

6

8

10

[DCB] (µM)

B Inhibition of NCX 1.1 by DCB (reverse mode)
1.0

IDCB/IControl

0.8
0.6

K1/2=22 µM

0.4
0.2
0.0
0

50

100

150

200

250

300

[DCB] (µM)
Fig. 4 – Representative whole-cell voltage clamp data used to
determine the IC50 for inhibition of NCX1.1 by DCB. The graph
depicts the data plot and the curve-fit line calculated used to
determine the IC50 for inhibition of both the (A) forward and
(B) reverse modes of NCX1.1.

2.9.
Treatment with Amiloride or DCB kills glioma cells
without increased caspase activation and produces nuclear
morphology inconsistent with apoptosis
Immunoblot analyses showed that treatment of normal
primary astrocytes or U87 glioma cells with amiloride
(250 μM) or DCB (20 μM) did not significantly increase activa
tion of caspases 3 or 7 (Fig. 5). As a positive control for
apoptosis, Staurosporine (10 μM) activated caspase 7 in astro
cytes and U87 glioma cells, while activating caspase 3 in
glioma cells. Treating glioma cells with either amiloride or
20 μM DCB, while cytotoxic, did not produce typical apoptotic
changes in nuclear morphology in U87 glioma cells stained

Discussion

In this study, [Na+]i is elevated more than 3 fold in U87 and C6
glioma cells as compared with normal astrocytes. This marked
elevation in [Na+]i appears to primarily depend upon persis
tent NHE1 activity and is sufficient to depolarize glioma cells
in hypoxic ischemic tumor regions where Na/K ATPase
activity is limited by non oxidative glycolysis (Gorin et al.,
2004; Erecinska et al., 1993). These ionic measurements are
consistent with reported U87 glioma membrane potentials of
( 48 to +15 mV) (Ducret et al., 2003), as compared with 78 mV
recorded in normal astrocytes (Perez Velazquez et al., 1996).
This magnitude of depolarization is sufficient to increase
[Ca2+]i in glioma cells as a consequence of activating voltage
dependent calcium channels, calcium dependent, store oper
ated channels (SOC) (Hartmann and Verkhratsky, 1998; Kovacs
et al., 2005), and can activate calcium loading by reversal of the
sodium calcium transport (NCX 1.1), as we reported in stretch
injured, depolarized astrocytes (Floyd et al., 2005). Here, we
identified that [Ca2+]i is increased by more than 5 fold and
associated with elevated [Na+]i in U87 glioma cells as compared
with normal astrocytes. The ionic imbalances identified in
malignant glioma cells in a bicarbonate depleted environment
present an opportunity for novel drug targeting strategies by
analyzing the cytotoxic consequences of markedly augmented
[Na+]i and [Ca2+]i in glioma cells.
We evaluated a mechanistic model where persistently
elevated cytosolic calcium in glioma cells is buffered by the
endoplasmic reticulum and mitochondria and additional
increases in cytosolic calcium are moderated by sodium
dependent calcium efflux through NCX1.1 (Fig. 1, panel A).
Ionomycin, a bacterial ionophore, produces a much greater
and persistent increase in cytosolic calcium when compared
with increased [Ca2+]i released from the ER by thapsigargin in
the same cell population (Fig. 3B). Direct glioma cytotoxicity by
ionomycin appears to arise by overwhelming intracellular
calcium buffering and sodium mediated calcium efflux by
NCX 1.1 (Fig. 1, panel B). Inhibiting NHE1 with the reversible
non fluorescent inhibitor, HOE694, reduced [Na+]i, but did not
demonstrably alter elevated levels of [Ca2+]i because of (1)
intracellular calcium buffering and (2) sodium dependent
calcium extrusion by NCX1.1 forward transport. Increased
intracellular calcium buffering by the ER in glioma cells is
demonstrated by the increased release of cytosolic free
calcium from TG sensitive ER stores in glioma cells, as
compared with astrocytes. Similarly, increased mitochondrial
calcium buffering in glioma cells is shown by increased
cytosolic free calcium following collapse of the transmito
chondrial membrane potential (ψm) using FCCP. Mitochondria
of several glioblastoma cell lines have been reported to
sequester millimolar quantities of [Ca2+]i (Hartmann and
Verkhratsky, 1998). In contrast, normal primary astrocytes
have 5 fold lower levels of [Ca2+]i than the U87 and C6 glioma
cells, and do not demonstrate an observable increase in
cytosolic free calcium following mitochondrial depolarization.

Table 1 – Treatment summary of cytotoxicities and cell viabilities for human malignant glioma cell lines. Cell death is
expressed as a percentage of trypan blue positive cells per total cell count. Viable cell number is expressed as a percentage of
the absorbance compared with time-matched, untreated controls utilizing a tetrazolium-based live cell assay (WST), which
was standardized to cell number for each cell line. Asterisks (*) or (**) indicates statistical significance at p < 0.05 or p < 0.005,
respectively. Abbreviations: NHE1: sodium–proton exchanger, isoform 1; NCX1: sodium–calcium exchanger, isoform 1.1.
Inhibition
Treatment after 48 h

U87

U251

U118

NHE NCX Cell death Viable cells Cell death Viable cells Cell death Viable cells
(SE)
(SE)
(SE)
(SE)
(SE)
(SE)

Control

3 (0.32)

Dual NHE1 + NCX inhibitors
Amiloride (500 μM)
DCB (20 μM)

+
+

NCX inhibitor
DCB (1 μM)
SEA400 (1 μM)

+
+

+

NHE1 + NCX inhibitor
Cariporide (100 μM) + DCB (1 μM)
Cariporide (100 μM) + DCB (1 μM) + zVAD.
FMK(200 μM)
Cariporide (100 μM) + SEA400 (1 μM)
Cariporide (100 μM) +
SEA400(1 μM) + zVAD.FMK(200 μM)

6 (1.5)

16** (3.3)
12** (0.9)

56** (4.1)
34** (3.6)

6 (1.5)
5 (0.86)

89* (1.2)
96 (2.2)

8 (1.9)
2 (1.5)

2 (0.43)

102 (1.6)

4 (0.59)

47** (2.7)
22** (2.1)

+
+

NHE1 inhibitor
Cariporide (100 μM)

100 (2.3)

+
+

+
+

39** (4.2)
34** (1.9)

35** (3.0)
47** (2.8)

+
+

+
+

15* (3.0)
18* (3.1)

82* (4.5)
87* (1.2)

This increased intracellular buffering in glioma cells is
demonstrated by the higher release of cytosolic free calcium
from TG sensitive ER stores and calcium release from FCCP
responsive mitochondrial stores. Basally elevated levels of
[Ca2+]i in glioma cells are associated with increased intracel
lular buffering as compared with normal astrocytes.
The intracellular release of calcium from ER or mitochon
drial stores of U87 glioma cells caused transitory elevations in
[Ca2+]i with restoration to near basal levels within 400 s.
Significantly, restoration of basal levels of [Ca2+]i following
TG treatment was prevented by inhibiting sodium dependent
calcium efflux (forward mode) by NCX1.1 (Fig. 1, panel A). The
whole cell patch recordings of CHO cells transfected with
NCX1.1 determined that DCB is a nanomolar inhibitor of the

Astrocytes
DMSO Amil.

DCB

100 (0.89)

5 (2.1)

100 (1.9)

63** (5.2)
44** (2.7)

28** (4.6)
37** (1.1)

95 (0.76)
95 (3.2)

11 (3.8)
3 (2.2)

81* (5.1)
102 (1.9)

98 (2.8)

4 (1.2)

99 (3.8)

69* (2.6)
87* (1.9)

25* (3.6)
20* (2.9)

77* (3.1)
82* (4.2)

28** (2.3)
38** (1.7)

17* (3.5)
21* (4.4)

forward mode of NCX1.1 and a micromolar inhibitor of the
reverse mode. To our knowledge, this is the first report
quantifying these large differences between inhibition of the
forward and reverse modes of NCX1.1 by DCB in an intact cell
and validated the use of DCB at low concentrations in glioma
cells to selectively inhibit the forward mode of NCX1.1. Neither
≤1 μM of DCB nor the use of selective nanomolar inhibitors of
the reverse mode of NCX1.1, SEA0400 (Table 1) or KB R79433
(Hegde et al., 2004), evoked glioma cytotoxicity. These
pharmacological data coupled with the fura 2 measurements,
demonstrated that inhibiting only the forward mode of
NCX1.1 was not sufficient to explain the glioma cytotoxicity
observed using higher concentrations of either amiloride or
DCB (Table 1).

U87
DMSO Amil.

Astro.
DCB

U87

Staurosporine

csps-7
csps-3
actin
Fig. 5 – Immunoblots of U87 glioma cells and primary astrocytes demonstrate changes in levels of cleaved caspases 3 and 7
(arrowheads) following drug or vehicle (0.1% DMSO) treatments. Staurosporine (10 μM) was included as a positive control to
demonstrate caspase activation in glioma cells and astrocytes undergoing apoptosis.

Amiloride is a more potent inhibitor of sodium proton
transport (NHE1) than of sodium calcium transport (NCX1.1),
but at higher concentrations (≥250 μM) demonstrates inhibi
tion of both transporters (Rogister et al., 2001). Conversely,
DCB inhibits NCX1.1 ≫ NHE1, but at higher concentrations
(≥20 μM), inhibits both modes of NCX1.1 and NHE1 in U87
glioma cells(Hegde et al., 2004). Consistent with a model
comprised of dual inhibition of NCX1.1 and NHE1, low
concentration DCB (≤ 1 μM) inhibits the forward mode of
NCX1.1, yet is not cytotoxic to glioma cells until achieving
concentrations (≥20 μM) which also inhibit NHE1 (Fig. 1, panel
B). Previously we reported that 50 μM of amiloride inhibits
NHE1 yet does not kill glioma cells until reaching concentra
tions that dually inhibit NCX1.1 and NHE1 (Hegde et al., 2004).
Employing 1 uM SEA0400 blocked both modes of NCX1.1 and
coupled with the NHE1 inhibitor Cariporide, caused glioma cell
death while neither agent alone was cytotoxic (Table 1).
Analogously, low concentration DCB (1 μM) blocked the
forward mode of NCX1.1 and when coupled with Cariporide
also triggered cell demise. These drug combinations, like
amiloride and 20 μM DCB, were comparably cytotoxic in the
presence or absence of pan caspase inhibitors.
Neither the NHE1 inhibitor, Cariporide, or either of the
NCX1.1 inhibitors, SEA0400 or DCB (1 μM) were individually
cytotoxic to the U87, U251 or U118 human glioma cell lines,
which had been previously shown to persistently activate
NHE1 and maintain basally elevated pHi (McLean et al., 2000).
However, dual inhibition of NHE1 and NCX1.1 by Cariporide +
SEA0400 or Cariporide + DCB (1 μM) was cytotoxic to these
glioma cell lines. Dual blockade of NHE1 and NCX1.1 using
different inhibitors in the three glioma cell lines demonstrates
a consistent pattern of cytotoxic potencies (Table 1). Amiloride
or high concentration DCB (20 μM) are consistently more
cytotoxic than either Cariporide + SEA0400 or Cariporide +
DCB (1 μM). The additional cytotoxicities of amiloride or
20 μM DCB may result from their enhanced inhibitor
potencies of the ionic transporters or indicate the possibility
of additional drug targeting. Furthermore, amiloride appears
to have additional cytostatic activity as its reduction of
viable cells exceeds the dead cell counts after 24 h in these
glioma cell lines (Table 1).
The caspase independent glioma cell demise triggered by
dual inhibition of NHE1 and NCX1.1 is supported by the
absence of observed caspase 3 or 7 activation associated with
drug treatment. Additionally, the nuclei of these dying glioma
cells did not adopt an apoptotic morphology (Fig. 1S). These
data support our prior observations that amiloride induced
glioma cell death did not activate PARP or Annexin V using
FACS analyses (Hegde et al., 2004). Several types of non
apoptotic cell death including autophagy and paraptosis have
been described that are relevant to cancer therapeutics
(Constantinou et al., 2009), and we are currently investigating
glioma cell death mechanisms triggered by these agents.
The precise intracellular mechanism(s) by which dual
inhibition of NHE1 and NCX1.1 produces selective glioma cell
death is unknown at this time. Dual inhibition of NHE1 and
NCX1.1 in glioma cells reduces pHi and could activate ASICs
with the increased calcium influx additionally increasing high
basal [Ca2+]i. Alternatively, further elevations in calcium
release from thapsigargin sensitive ER stores in glioma cells

have been reported to activate store operated calcium (SOC)
channels that could augment calcium influx and increase [Ca2+]i
to cytotoxic levels when the forward mode of NCX1.1 is
inhibited (Kovacs et al., 2005). These pharmacological studies
indicate that sodium dependent proton and calcium efflux by
ionic transporters assist malignant glioma cells to survive in
hypovascularized, acidotic tumor microenvironments and
potentially represent important pharmacological targets.

4.

Experimental procedures

4.1.

Glioma cell lines and primary astrocyte cultures

Human U87 and rat C6 glioma cell lines were obtained from the
American Tissue Culture Collection. Primary rat astrocytes
were isolated from the cerebral cortices of neonatal Sprague
Dawley rats (1 2 days old) as described in detail elsewhere
(Floyd et al., 2005). Briefly, cortices were cleaned of meninges
and white matter, mechanically disseminated, and incubated
with papain for 30 min. Astrocyte culture purity was charac
terized as 98% using GFAP immunocytochemistry as described
previously (Amruthesh et al., 1993). Glioma cells and astrocytes
were grown on rat tail collagen coated coverslips in DMEM
supplemented with 10% fetal bovine serum (Hyclone), 1% L
glutamine (200 mM, Gibco), 100 U/ml penicillin and 100 mg/ml
streptomycin (Gibco) as detailed in Hegde et al. (2004).

4.2.

Cytosolic free sodium and calcium determinations

[Na+]i and [Ca2+]i were determined using either SBFI AM or
Fura 2 AM, respectively, as described previously (Floyd et al.,
2005). Glioma cells were grown on collagen coated coverslips
at 37 °C. Cells were washed and then loaded with SBFI AM or
Fura 2 AM at RT to control esterase activity and reduce non
specific dye uptake by intracellular organelles and then
imaged at 37 °C as described in detail elsewhere (Floyd et al.,
2005). Cells were rinsed twice and then loaded in HEPES
buffered saline with 5 μM Fura 2 AM (60 min) or 20 μM SBFI
AM + 0.1% pluronic acid (90 min) at room temperature (20
22 °C) and rinsed before imaging. During the experiments,
cells were perfused (flow rate 5 ml/min) with 37 °C HEPES
buffered saline and bath temperature monitored and main
tained with a Peltier controlled open incubation system
(Harvard Apparatus, Holliston, MA).
Intracellular imaging was conducted on a high speed
imaging system with excitation light provided by a xenon
arc lamp coupled to a Polychrome IV scanning monochroma
tor (Till Photonics, Grafelfing, Germany) that can alternate
excitation wavelengths. Excitation light was delivered to cells
via fiber optics through the epifluorescence port of a Nikon
E600 microscope coupled to a Nikon Fluor 60× water immer
sion lens. The detector was an Orca II ER CCD digital camera
(Hamamatsu USA, Bridgewater, NJ) that is computer con
trolled by C Imaging SimplePCI software (Compix, Cranberry
Township, PA). For in vitro ionic measurements, individual cell
values from a microscope field (4 7 cells/field) were averaged
for each experimental condition. Each experimental condition
was repeated a minimum of 3 times totaling 12 21 cells/
condition (Floyd et al., 2005).

Calibration of SBFI fluorescent emission to [Na+]i was
performed using the method described previously (Floyd et al.,
2005). Cells were perfused with HR containing 3 μM gramicidin,
100 μM ouabain, and sodium concentrations of 0, 30, or 50 mM.
Data were compared to a standard curve generated by perfusing
another set of cells with the aforementioned ionophores in the
presence of varying buffer containing sodium (0, 10, 30, 50, 70, and
100 mM). Calibration of Fura 2 with [Ca2+]i utilized the ratiometric
method described elsewhere (Grynkiewicz et al., 1985). Rmin and
Rmax values (340/380 excitation with 505 nM emission) were
determined by perfusing cells with HR plus 10 μM ionomycin and
either 10 mM EGTA or 5 mM calcium, respectively.
CHO cells stably transfected with NCX1.1 was a kind gift from
John Reeves (Reeves and Condrescu, 2003). CHO cells were
transfected with the mammalian expression vector pcDNA3
containing the open reading frame for the bovine cardiac Na+/
Ca2+ exchanger (NCX1.1; accession number LO6438) with
functional recombinants selected using ionomycin. Stable
transfectants were maintained in the presence of the antibi
otic G418.

4.3.

Measurement of NCX1.1 exchange current

Whole cell current recordings were performed as described
elsewhere (Chen and Yau, 1994) using an Axopatch 200B
amplifier. Currents were digitally filtered at 1 kHz and
digitized at 2 kHz using Digidata 1320 digitizer and pClamp8
software (Axon Instrument/Molecular Device). Borosilicate
glass electrodes were pulled by PP 830 Puller (Narashige Co.),
and have a resistance of 1.5 2.0 MΩ when filled with the
pipette solution. To record the NCX 1.1 exchanger activity, the
clamped whole cell was moved to the mouth of a set of
capillary tubes which were controlled by SF 77 solution
exchanger (Warner Instruments) and pClamp8 software. The
cell was exposed to the control solution and work solution
sequentially to monitor the exchanger currents, the clamping
potential is 0 mV.

4.3.1.

Forward mode NCX1.1

For inward sodium current recording, the pipette solution
contained (in mM) 120 LiCl, 20 tetramethylammonium chloride
(TEA Cl), 5 KCl, 2 MgCl2, 8 D glucose, 10 HEPES, 2 nitrilotriacetic
acid (NTA), and 0.346 CaCl2 (20 μM free Ca2+), pH 7.2; the bath
control solution contained (in mM) 145 LiCl, 1 MgCl2, 10 D
glucose, 10 HEPES, and 1 EGTA, pH 7.4; and the bath work
solution contained (in mM) 145 NaCl, 1 MgCl2, 10 D glucose, 10
HEPES, and 1 EGTA, pH 7.4.

4.3.2.

Reverse mode NCX1.1

For outward current recording, the pipette solution contained
(in mM) 120 NaCl, 5 KCl, 2 MgCl, 8 D glucose, 20 tetramethy
lammonium chloride (TEA Cl), 4.28 CaCl2, 5 EGTA, and 10
HEPES, pH 7.2; the bath control solution contained (in mM) 145
LiCl, 1 MgCl2, 10 D glucose, 0.5 EGTA, and 10 HEPES, pH 7.4;
and the bath work solution contained (in mM) 145 LiCl, 1
MgCl2, 10 D glucose, 1 CaCl2, and 10 HEPES, pH 7.4. For inward
current recording, the pipette solution contained (in mM) 120
LiCl, 20 TEA Cl, 5 KCl, 2 MgCl2, 8 D glucose, 10 HEPES, 2
nitrilotriacetic acid (NTA), and 0.346 CaCl2 (20 μM free Ca2+),
pH 7.2; the bath control solution contained (in mM) 145 LiCl, 1

MgCl2, 10 D glucose, 10 HEPES, and 1 EGTA, pH 7.4; and the
bath work solution contained (in mM) 145 NaCl, 1 MgCl2, 10 D
glucose, 10 HEPES, and 1 EGTA, pH 7.4.
For drug application, DCB was prepared as stock solutions
in DMSO stored at 30 °C. Upon use, the stock solutions were
diluted to certain concentrations by bath control or work
solutions. To test the drug effects, sodium currents in the
absence of drugs were first recorded, and immediately
followed by a recording in the presence of certain concentra
tions of drugs. All experiments were conducted at the room
temperature. Data analysis normalized the current under drug
treatment conditions to that in the absence of drugs. The
normalized value was fitted to a Langmüir function to
estimate the half inhibition concentration (IC50). All data
points come from the average of 3 5 independent recordings.
The data are presented by mean ± standard deviation (SD).

4.4.

Viable cell number and cytotoxicity determination

96 well plates were initially seeded with 104 U87 cells in media
described earlier and allowed to adhere for 24 h. Stock drug
concentrations were dissolved in DMSO and added to the
media with a final vehicle concentration of 0.1% DMSO.
Following treatment, 10 μl of water soluble tetrazolium (10%
v/v, WST, Roche) was added, the plate shaken for 5 s, and read
on a plate reader 3 h after the addition of tetrazolium dye.
Viable cell numbers, measured as absorbance values, were
normalized using control curve determined for each cell type.
Cells were removed by gentle rinsing with PBS following
absorbance determinations. Trypan blue was added to cell
suspension (10% v/v) and after 5 min an aliquot was trans
ferred to a manual hemacytometer for cell counting.

4.5.

Nuclear morphology cell death studies

Treated and stage matched, vehicle treated cells were evalu
ated for cell death in the presence of zVAD FMK (20 μM), a pan
caspase inhibitor, and the results were averaged from at least
six experiments. The nuclei of treated and untreated glioma
cells were stained with 10 μM Hoechst 33342 (Sigma) for
30 min and visualized on a Nikon E600 fluorescent
microscope.

4.6.

Immunoblotting

Cells in six well plates were lysed with 300 μl Laemmli buffer
(0.03 M Tris HCl, 0.02% SDS, 0.5 M β mercaptoethanol, 7%
glycerol, and 0.01% bromophenol blue) and boiled for 10 min at
90 °C. The lysates were fractionated by molecular weight using
dodecyl sulfate polyacrylamide gel electrophoresis, trans
ferred to nitrocellulose (Bio Rad Laboratories), blocked for 1 h
in TBS Triton containing 5% dried milk, and blotted with the
antibodies indicated in the figures. Horseradish peroxidase
conjugated secondary antibodies and SuperSignal detection
reagents (West Femto and West Pico from Pierce and Thermo
Scientific, respectively) were used for detection, and chemilu
minescent images were captured using an Alpha Innotech
imaging station. Mouse anti β actin AC 15 was purchased
from Sigma. Rabbit anti cleaved caspase 3 and rabbit anti
cleaved caspase 7 were purchased from Cell Signaling

Technologies. Horseradish peroxidase conjugated goat anti
mouse IgG and horseradish peroxidase conjugated goat anti
rabbit IgG were from Zymed and Pierce, respectively.

4.7.

Statistical analysis

Data in Table 1 are presented as mean ± standard error of the
mean (SEM). Statistical significance was determined for cell
number and cytotoxicity using one way analysis of variance
and Bonferroni's test for multiple pairwise comparisons using
SigmaStat software version 2.00 (SPSS Science Inc, Chicago, IL).
Supplementary materials related to this article can be
found online at doi: 10.1016/j.brainres.2010.09.059.
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